A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|Endometrial Cancer
Interventions: DRUG: LY3484356|DRUG: Abemaciclib|DRUG: Everolimus|DRUG: Alpelisib|DRUG: Trastuzumab|DRUG: Aromatase Inhibitor (AI)|DRUG: Pertuzumab
Sponsor: Eli Lilly and Company